

Part B Drug Authorization List Changes

August 2026

New prior authorization requirements starting September 1, 2026

- Lumvoa (veligrotug-vvze), HCPCS code J3590
- Tregzi (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq), HCPCS code J3590

HCPC code updates effective July 1, 2026

- Enoby/Xtrenbo (denosumab-qbde) Q5167
- Exdensur(depemokimab-ulaa) Q2361
- Itvisma (onasemnogene abeparvovec-brve) J3405
- Qivigy (human immune globulin) J1577
- Starjemza® IV (ustekinumab-hmny) Q5164
- Waskyra (etuvetidigene autotemcel) J3386
- Yartemlea (narsoplimab-wuug) J1289

Prior authorization removal effective July 1, 2026

- Zinplava, HCPCS code J0565 (withdrawn from U.S. market by manufacturer)

Refer to the *Part B Medical Drug Prior Authorization & Step Therapy List* and/or the *Part B Medical Drug Policy Criteria* documents under [Provider Resources](#) of our website for detailed requirements.

Submit prior authorization through one of the following methods:

- Electronically through Symphony, the authorization tool located in the Wellmark Advantage Health Plan Provider Portal.
- Fax: download Part B medical drug prior [authorization form](#) [wellmark.com/provider/medicare-advantage](https://www.wellmark.com/provider/medicare-advantage) and fax to (877) 218-0941.
- Call: (855) 673-4225.